MREO241220C4000
- 0.20
- -0.05-20.00%
Mereo BioPharma Newsroom
Mereo BioPharma Files for Common Stock Offering by Holders
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)
Mereo BioPharma: Strong Cash Position Amid Clinical Progress
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
Mereo BioPharma | 8-K: Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mereo BioPharma | 10-Q: Quarterly report
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
Mereo Biopharma Group: Anticipated Positive Developments and Strong Financial Position Justify Buy Rating
Mereo BioPharma Group Q3 2024 GAAP EPS $(0.02) Misses $1.31 Estimate
Mereo BioPharma Group 3Q Loss/Shr 2c >MREO
Press Release: Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
Baird Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $8
Baird analyst Jack Allen maintains $Mereo BioPharma(MREO.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 32.9% and a total
Mereo BioPharma Group Plc (MREO): A Bull Case Theory
Mereo BioPharma Group Down Over 9%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk
Mereo BioPharma CFO Sells Over $121k in Company Stock